Summary of findings 3. ART alone compared to Vincristine or Bleomycin for Kaposi sarcoma in children with HIV‐1 infection.
| ART alone compared to Vincristine or Bleomycin for Kaposi sarcoma in children with HIV‐1 infection | ||||||
| Patient or population: Kaposi sarcoma in children with HIV‐1 infection Settings: Intervention: ART alone Comparison: Vincristine or Bleomycin | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Vincristine or Bleomycin | ART alone | |||||
| Complete Response | Study population | RR 1.2 (0.13 to 11.43 ) | 24 (1 Studies) | ⊕⊝⊝⊝ VERY LOW | ||
| 1/9 (11.1)% | 133 per 1000 (14 to 1270) | |||||
| Complete or Partial Response | Study population | RR 0.2 (0.05 to 0.79 ) | 24 (1 Studies) | ⊕⊝⊝⊝ VERY LOW | ||
| 6/9 (66.7)% | 133 per 1000 (33 to 527) | |||||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1No explanation was provided
2Unadjusted Estimates
3<50 cases